{"id":422826,"date":"2025-10-28T00:00:00","date_gmt":"2025-10-28T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0045-2025-biopharma-atopic-dermatitis-atopic-eczema-current-treatment-treatment-algorithms-claims-data-analysis\/"},"modified":"2026-04-28T11:10:30","modified_gmt":"2026-04-28T11:10:30","slug":"algoim0045-2025-biopharma-atopic-dermatitis-atopic-eczema-current-treatment-treatment-algorithms-claims-data-analysis","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0045-2025-biopharma-atopic-dermatitis-atopic-eczema-current-treatment-treatment-algorithms-claims-data-analysis\/","title":{"rendered":"Atopic Dermatitis \/ Atopic Eczema &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Adult Atopic Dermatitis (US)"},"content":{"rendered":"<p><abbr title=\"atopic dermatitis\">AD<\/abbr> is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin. <abbr title=\"atopic dermatitis\">AD<\/abbr> typically develops in early childhood and can persist into adulthood. Topical immunotherapy is the first-line mainstay therapy, but in topical-refractory patients, symptoms are managed with systemic therapies. The launch of targeted <abbr title=\"atopic dermatitis\">AD<\/abbr> therapies such as biologics from Sanofi \/ Regeneron (Dupixent [dupilumab]) and LEO Pharma (Adbry [(tralokinumab]), two oral <abbr title=\"Janus kinase\">JAK<\/abbr> inhibitors (AbbVie\u2019s Rinvoq [upadacitinib] and Pfizer\u2019s Cibinqo [abrocitinib]), one topical <abbr title=\"Janus kinase\">JAK<\/abbr> inhibitor (Incyte\u2019s Opzelura [ruxolitinib]), and a topical aryl hydrocarbon receptor agonist (Dermavant\u2019s Vtama [tapinarof 1% cream]) have greatly expanded the treatment options for adult <abbr title=\"atopic dermatitis\">AD<\/abbr> patients across the severity spectrum. This claims data analysis explores usage patterns of these newer therapies relative to historical mainstays of treatment and provides valuable insight into evolving U.S. drug-treatment trends in <abbr title=\"atopic dermatitis\">AD<\/abbr>.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult <abbr title=\"atopic dermatitis\">AD<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult <abbr title=\"atopic dermatitis\">AD<\/abbr> patients?<\/li>\n<li>How have Cibinqo, Rinvoq, and Vtama been integrated into the treatment algorithm, and what are their sources of business?<\/li>\n<li>What percentage of adult <abbr title=\"atopic dermatitis\">AD<\/abbr> patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of adult <abbr title=\"atopic dermatitis\">AD<\/abbr> patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><b>Geography: <\/b>United States<\/p>\n<p><strong>Real-world data:<\/strong> Longitudinal patient-level claims data analysis<\/p>\n<p><strong>Key drugs covered:<\/strong> Adbry, Cibinqo, Dupixent, Opzelura, Rinvoq, Vtama, oral immunosuppressants, corticosteroids (topical and oral), topical calcineurin inhibitors<\/p>\n<p><strong>Key feature:<\/strong> Dashboard featuring interactive visuals, easy navigation, and expanded analyses<\/p>\n<p><strong>PRODUCT DESCRIPTION <\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p><strong>Product enhancement<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n","protected":false},"template":"","class_list":["post-422826","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/422826","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/422826\/revisions"}],"predecessor-version":[{"id":553455,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/422826\/revisions\/553455"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=422826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}